SARCOMATOID RENAL CELL CARCINOMA
Clinical trials for SARCOMATOID RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new SARCOMATOID RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for SARCOMATOID RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of a combination of two or three drugs (cabozantinib, nivolumab, and possibly ipilimumab) in people with advanced genitourinary cancers that have spread. About 152 adults with these cancers will participate. The goal is to fin…
Matched conditions: SARCOMATOID RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 13:54 UTC
-
Immunotherapy combo may keep kidney cancer at bay after surgery
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to standard kidney cancer surgery can stop the cancer from returning. About 819 people with localized kidney cancer took part. The approach aims to boost the immune system to attack any remaining cancer cells after …
Matched conditions: SARCOMATOID RENAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could a superfruit boost immunotherapy for kidney cancer?
Disease control OngoingThis early-phase trial tests adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) for people with advanced kidney cancer that has spread. The main goal is to find the safest dose and see how it affects gut bacteria. About 31 participants will …
Matched conditions: SARCOMATOID RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for rare kidney cancers? drug combo trial shows promise
Disease control OngoingThis study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 adults will take the drugs until their disease gets worse or side effects become too severe. The goal is to see if…
Matched conditions: SARCOMATOID RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
Head-to-Head: which drug works better for rare kidney cancer?
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at controlling the cancer. About 32 participants w…
Matched conditions: SARCOMATOID RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New combo therapy shows promise in advanced kidney cancer trial
Disease control OngoingThis phase 3 trial tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with untreated, metastatic clear cell renal cell carcinoma are participating. Th…
Matched conditions: SARCOMATOID RENAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:03 UTC